Stocks and Investing Stocks and Investing
Wed, March 29, 2023
Tue, March 28, 2023
Mon, March 27, 2023
Fri, March 24, 2023

Michael Ulz Maintained (SNTI) at Hold with Decreased Target to $20 on, Mar 24th, 2023


Published on 2024-10-28 02:25:14 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Senti Biosciences, Inc." (SNTI) at Hold with Decreased Target from $30 to $20 on, Mar 24th, 2023.

Michael has made no other calls on SNTI in the last 4 months.



There are 2 other peers that have a rating on SNTI. Out of the 2 peers that are also analyzing SNTI, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Cheng of "JP Morgan" Initiated at Hold on, Friday, December 16th, 2022


This is the rating of the analyst that currently disagrees with Michael


  • Geulah Livshits of "Chardan Capital" Maintained at Strong Buy with Decreased Target to $70 on, Thursday, March 23rd, 2023